Analysis: hausen pharmaceutical industry innovative drug R & D pipeline

Haosen Pharmaceutical Co., Ltd., founded in 1995, is a leading enterprise in research and development and production of anti-tumor and psychotropic drugs in China It ranks among the top 30 pharmaceutical enterprises in China and is a leading innovative modern pharmaceutical enterprise in China In recent years, Haosen pharmaceutical industry is consolidating its own advantageous products, and is also improving its own innovative drug research and development pipeline step by step, and the whole innovation system has formed a scale, and reaped a lot The innovative drug pipeline has a general overview of Howson pharmaceutical industry, and its achievements in innovative drugs At present, it has one "class 1" listed drug in China, two products for NDA application; two clinical phase 3 candidate drugs, three phase 2 candidate drugs, and 14 phase 1 candidate drugs Although the drug R & D pipeline is not very strong, it has taken shape and formed its own innovative drug R & D pipeline In the field of treatment, hausen pharmaceutical focuses on anti-tumor, anti infection, endocrine and metabolic diseases Figure 1 overview of hausen pharmaceutical - Innovative Drug Pipeline Haosen Pharmaceutical Co., Ltd has one brand-new drug variety of "China class 1", i.e ~ molinnidazole, which was listed in 2014 Currently, there are two varieties in NDA status, namely, flumatenib mesylate, which is used to treat chronic myelocytic leukemia, and losenin polyethylene glycol, which is used to treat type 2 diabetes (developed jointly with Hengrui) See Table 1 for details Molindazol Morpholinidazole, developed by Jiangsu Haosen Pharmaceutical Co., Ltd., is a nitroimidazole antibiotic The mechanism of its anti microbial effect may be the reduction of nitro group in its molecule to amino group or the formation of free radicals in the anaerobic environment, and the interaction with cell components, resulting in the death of microorganisms On February 24, 2014, it was approved by China food and Drug Administration for listing It is marketed in China by hausen Pharmaceutical Co., Ltd under the trade name of Melinda ®; Melinda is an intravenous injection, containing 500mg of morpholinidazole in 100ml each bottle; the recommended dose is intravenous drip, 500mg each time, twice a day, with an interval of 6-8 hours, for 5-7 days [synthesis route] flumatenide [synthesis route] pegylated losenin [synthesis route] clinical phase 3 varieties] currently in clinical phase 3, there are 2 varieties, pegylated thymosin α 1 for the treatment of hepatitis B and glucosamine for the treatment of advanced breast cancer and pancreatic adenocarcinoma See Table 5 for details Currently, there are 3 clinical phase 2 varieties, including besgliptin tosilate for type 2 diabetes, hs-10296 for non-small cell lung cancer, and peihuaxihematin for myelodysplastic syndrome See Table 6 for details Clinical phase 1 varieties are currently in clinical phase 1 varieties, there are more than ten, and the indications are mainly concentrated in tumor and type 2 diabetes The corresponding target is also the hot target currently developed, see Table 7 for details As one of the four pharmaceutical enterprises in Lianyungang, Howson pharmaceutical has its own advantages and rich pharmaceutical details, and has grown from an early external technology input to a huge innovative enterprise in terms of technology and strength According to the ranking of domestic pharmaceutical enterprises released by various channels in recent years, hausen's reputation has just entered the first echelon of domestic pharmaceutical industry I believe that under the guidance of the spirit of self-improvement of the enterprise leader, the operation of hausen and the innovative drug R & D pipeline of hausen will surely go to a higher level! (it's really not a soft article...) reference: drug data drug administration official website enterprise official website